Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas

Human Gene Therapy

Volumn 25, Issue 2, 2014, Pages 132-143

  Rodriguez Madoz, Juan R ^a,c   Zabala, Maider ^a,d   Alfaro, Maite ^a   Prieto, Jesus ^a,b   Kramer, M Gabriela ^a,e   Smerdou, Cristian ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Universidad de la Republica Instituto de Higiene   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; PLASMID VECTOR; SEMLIKI FOREST ALPHAVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; GENETIC TRAIT; HISTOPATHOLOGY; HYDRODYNAMICS BASED TRANSFECTION; LIVER; LIVER CELL CARCINOMA; MALE; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE C MYC; SEMLIKI FOREST ALPHAVIRUS; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM;

ALPHAVIRUS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; INJECTIONS, INTRALESIONAL; INTERFERON-GAMMA; INTERLEUKIN-12; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; SEMLIKI FOREST VIRUS; TRANSDUCTION, GENETIC;

EID: 84893532894     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.080     Document Type: Article

References (53)

1. Akira, S., and Hemmi, H. (2003). Recognition of pathogenassociated molecular patterns by TLR family. Immunol. Lett. 85, 85-95.
2. Andrews, K.J., Ribas, A., Butterfield, L.H., et al. (2000). Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Cancer Res. 60, 6457-6464.
3. Atkins, M.B., Robertson, M.J., Gordon, M., et al. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-417.
4. Barajas, M., Mazzolini, G., Genove, G., et al. (2001). Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 33, 52-61.
5. Berglund, P., Fleeton, M.N., Smerdou, C., and Liljestrom, P. (1999). Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17, 497-507.
6. Bernstein, D.I., Reap, E.A., Katen, K., et al. (2009). Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28, 484-493.
7. Berraondo, P., Prieto, J., and Gonzalez-Aseguinolaza, G. (2009). Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther. 9, 62-71.
8. Blondon, H., Fritsch, L., and Cherqui, D. (2004). Two cases of spontaneous regression of multicentric hepatocellular carcinoma after intraperitoneal rupture: possible role of immune mechanisms. Eur. J. Gastroenterol. Hepatol. 16, 1355-1359.
9. Cartier, N., Miquerol, L., Tulliez, M., et al. (1992). Diet-dependent carcinogenesis of pancreatic islets and liver in transgenic mice expressing oncogenes under the control of the L-type pyruvate kinase gene promoter. Oncogene 7, 1413-1422.
10. Caruso, M., Pham-Nguyen, K., Kwong, Y.L. et al. (1996). Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA 93, 11302-11306.
11. Colmenero, P., Chen, M., Castanos-Velez, E., et al. (2002). Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer 98, 554-560.
12. Chikkanna-Gowda, C.P., Sheahan, B.J., Fleeton, M.N., and Atkins, G.J. (2005). Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther. 12, 1253-1263.
13. Daud, A.I., DeConti, R.C., Andrews, S., et al. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26, 5896-5903.
14. de La Coste, A., Mignon, A., Fabre, M., et al. (1999). Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res. 59, 5017-5022.
15. Del Vecchio, M., Bajetta, E., Canova, S., et al. (2007). Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13, 4677-4685.
16. Edmondson, H.A., and Steiner, P.E. (1954). Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7, 462-503.
17. Guan, M., Rodriguez-Madoz, J.R., Alzuguren, P., et al. (2006). Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. Cancer Res. 66, 1620-1629.
18. Hidmark, A.S., Nordstrom, E.K., Dosenovic, P., et al. (2006). Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J. Virol. 80, 7100-7110.
19. Kirkwood, J.M., Bender, C., Agarwala, S., et al. (2002). Mechanisms and management of toxicities associated with highdose interferon alfa-2b therapy. J. Clin. Oncol. 20, 3703-3718.
20. Lee, J.S., and Thorgeirsson, S.S. (2004). Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 127, S51-S55.
21. Lee, J.S., Chu, I.S., Mikaelyan, A., et al. (2004). Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 36, 1306-1311.
22. Leitner, W.W., Ying, H., Driver, D.A., et al. (2000). Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 60, 51-55.
23. Leitner, W.W., Hwang, L.N., Bergmann-Leitner, E.S., et al. (2004). Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22, 1537-1544.
24. Liljestrom, P., and Garoff, H. (1991). A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 9, 1356-1361.
25. Mahvi, D.M., Henry, M.B., Albertini, M.R., et al. (2007). Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial. Cancer Gene Ther. 14, 717-723.
26. Morse, M.A., Hobeika, A.C., Osada, T., et al. (2010). An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J. Clin. Invest 120, 3234-3241.
27. Penuelas, I., Mazzolini, G., Boan, J.F., et al. (2005). Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128, 1787-1795.
28. Quetglas, J.I., Ruiz-Guillen, M., Aranda, A., et al. (2010). Alphavirus vectors for cancer therapy. Virus Res. 153, 179-196.
29. Quetglas, J.I., Dubrot, J., Bezunartea, J., et al. (2012). Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol. Ther. 20, 1664-1675.
30. Quetglas, J.I., Rodriguez-Madoz, J.R., Bezunartea, J., et al. (2013). Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses. J. Immunol. 190, 2994-3004.
31. Reboredo, M., Kramer, M.G., Smerdou, C., et al. (2008a). Transcriptomic effects of Tet-on and mifepristone-inducible systems in mouse liver. Hum. Gene Ther. 19, 1233-1247.
32. Reboredo, M., Zabala, M., Mauleon, I., et al. (2008b). Interleukin-12 inhibits liver-specific drug-inducible systems in vivo. Gene Ther. 15, 277-288.
33. Riezebos-Brilman, A., Regts, J., Chen, M., et al. (2009). Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by coexpression of interleukin-12. Vaccine 27, 701-707.
34. Rodriguez-Madoz, J.R., Prieto, J., and Smerdou, C. (2005). Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol. Ther. 12, 153-163.
35. Rodriguez-Madoz, J.R., Prieto, J., and Smerdou, C. (2007). Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration. Mol. Ther. 15, 2164-2171.
36. Rodriguez-Madoz, J.R., Liu, K.H., Quetglas, J.I., et al. (2009). Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma. J. Virol. 83, 12266-12278.
37. Sangro, B., Mazzolini, G., Ruiz, J., et al. (2004). Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22, 1389-1397.
38. Sangro, B., Mazzolini, G., Ruiz, M., et al. (2010). A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther. 17, 837-843.
39. Schmitz, V., Tirado-Ledo, L., Raskopf, E., et al. (2005). Effective antitumour mono-and combination therapy by gene delivery of angiostatin-like molecule and interleukin-12 in a murine hepatoma model. Int. J. Colorectal. Dis. 20, 494-501.
40. Smerdou, C., and Liljestrom, P. (1999). Two-helper RNA system for production of recombinant Semliki forest virus particles. J. Virol. 73, 1092-1098.
41. Tahara, H., Zitvogel, L., Storkus, W.J., et al. (1995). Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154, 6466-6474.
42. Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146.
43. Triozzi, P.L., Allen, K.O., Carlisle, R.R., et al. (2005). Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin. Cancer Res. 11, 4168-4175.
44. Unitt, E., Marshall, A., Gelson, W., et al. (2006). Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol. 45, 246-253.
45. Vanrell, L., Di Scala, M., Blanco, L., et al. (2011). Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol. Ther. 19, 1245-1253.
46. Voest, E.E., Kenyon, B.M., O'Reilly, M.S., et al. (1995). Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581-586.
47. Waehler, R., Ittrich, H., Mueller, L., et al. (2005). Low-dose adenoviral immunotherapy of rat hepatocellular carcinoma using single-chain interleukin-12. Hum. Gene Ther. 16, 307-317.
48. Wang, L., Hernandez-Alcoceba, R., Shankar, V., et al. (2004). Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 126, 278-289.
49. Weiss, J.M., Subleski, J.J., Wigginton, J.M., and Wiltrout, R.H. (2007). Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin. Biol. Ther. 7, 1705-1721.
50. Ying, H., Zaks, T.Z., Wang, R.F., et al. (1999). Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 5, 823-827.
51. Zabala, M., Wang, L., Hernandez-Alcoceba, R., et al. (2004). Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors. Cancer Res. 64, 2799-2804.
52. Zabala, M., Lasarte, J.J., Perret, C., et al. (2007). Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J. Hepatol. 47, 807-815.
53. Zhang, G., Budker, V., and Wolff, J.A. (1999). High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735-1737.